Video

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, and member, Duke Cancer Institute, discusses the combination of ieramilimab (LAG525) and spartalizumab in advanced malignancies.

During the 2020 SITC Virtual Congress, investigators presented the results of an ongoing phase 2 multicenter trial evaluating the efficacy and safety of LAG525, a LAG-3 inhibitor, and spartalizumab, a PD-1 inhibitor.

The trial enrolled 235 patients with non–small cell lung cancer (n = 42), melanoma (n = 42), renal cell carcinoma (RCC; n = 38), mesothelioma (n = 57), and triple-negative breast cancer (n = 56).

In the RCC cohort, the overall response rate (ORR) was 26.3% in patients who had not received prior anti–PD-1/PD-L1 therapy and 5.3% in those previously treated with anti–PD-1/PD-L1 therapy.

Moreover, 5 patients with immunotherapy-naïve RCC achieved a partial response (PR), and 1 patient who was immunotherapy exposed achieved a PR with the combination.

Two patients with mesothelioma who were immunotherapy naïve and 1 patient with melanoma who had prior immunotherapy achieved complete responses with LAG525/spartalizumab, concludes Zhang.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity